Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Status:
Not yet recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic
radiosurgery. Specifically, to determine if this combination will lead to improved response
in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains
controlled).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Baptist Health South Florida
Collaborators:
Cantex Pharmaceuticals Inc. Miami Cancer Institute